PROTEOMICS: TECHNOLOGIES AND GLOBAL MARKETS



BIO034D February 2015

John Bergin **Project Analyst**

ISBN: 1-62296-046-7



BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481 USA
866-285-7215 (toll-free within the USA),
or (+1) 781-489-7301
www.bccresearch.com
information@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THE STUDY	2
CONTRIBUTION OF THE STUDY AND INTENDED AUDIENCE	3
SCOPE AND FORMAT	3
METHODOLOGY	3
INFORMATION SOURCES	4
RELATED BCC RESEARCH REPORTS	4
ANALYST'S CREDENTIALS	4
BCC RESEARCH ONLINE SERVICES	5
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY,	
THROUGH 2019 (\$ MILLIONS)	7
SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY,	7
2013-2019 (\$ MILLIONS)	,
CHAPTER 3 OVERVIEW	11
PROTEOMIC TECHNOLOGIES	11
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS	12
SCOPE OF REPORT	13
TABLE 2 SCOPE OF REPORT	13
PROTEOMICS MARKET	13
TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	14
DRIVING FORCES FOR PROTEOMICS INDUSTRY GROWTH	15
TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	15
THE PROTEOMICS INDUSTRY	16
	16
TABLE 5 BIOCHIP INDUSTRY COMPARISONS	10
CHAPTER 4 PROTEOMICS TECHNOLOGIES	18
INTRODUCTION TO TECHNOLOGY PLATFORMS	18
FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC	18
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS	19
MS-BASED PROTEOMICS TECHNOLOGIES	20
SAMPLE PREPARATION ASSAYS	20
TAGGING/AFFINITY METHODS	21
MS INSTRUMENTS AND CONSUMABLES	22
TABLE 6 MASS SPECTROMETER PLATFORMS	23
BIOCHIP-BASED PROTEOMICS TECHNOLOGIES	23
TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES	23
TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS	24
MULTIPLEX PROTEOMICS SYSTEMS	25
TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS	25
PROTEOGENOMICS	27
RECENT ADVANCES IN PROTEOMIC TECHNOLOGIES	27

TOPIC	PAGE NO.
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS	28
CHAPTER 5 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	31
TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	31
TARGET DISCOVERY	31
LEAD IDENTIFICATION	33
LEAD OPTIMIZATION	33
PRECLINICAL STUDIES	34
CHAPTER 6 PROTEOMICS SCIENTIFIC INITIATIVES	36
TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES	36
CHAPTER 7 CLINICAL PROTEOMICS APPLICATIONS	41
TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN	41
CLINICAL SAMPLES	41
CANCER APPLICATIONS	42
CANCER OVERVIEW	42
TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS,	42
2010 AND 2013	
Bladder Cancer	43
TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS	43
Breast Cancer	44
Breast Cancer Screening	44
Prognosis and Pharmacogenetics Tests	45
TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	46
Breast Cancer MDx Platforms	46
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS	47
Status of Next Generation Breast Cancer Tests	48
TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS	48
Breast Cancer Early Detection/Screening Tests	50
Breast Cancer Risk Tests	51
Response to Chemotherapy; Recurrence Probability; Subtyping	52
Colorectal Cancer	55
Gastric Cancer	56
TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS	57
Kidney Cancer	57
TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS	58
Lung Cancer	59
TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)	59
TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS	60
Lymphomas	63
TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS	63
Ovarian Cancer	64
TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS	64
TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS	66

TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS Prostate Cancer TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS Thyroid Cancer TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS INFECTIOUS DISEASES TO DIABETES NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE SCHIZOPHRENIA MIMUNE DISEASES BI HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PRECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS CHAPTER 8 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 33 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 33 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 103 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 104 TABLE 39 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 104 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 105 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINAS BIOCHIP INDUSTRY 111 TABLE 44 CHINAS BIOCHIP INDUSTRY 111	TOPIC	PAGE NO.
Prostate Cancer TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS Thyroid Cancer TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS INFECTIOUS DISEASES DIABETES PROFUNDATION OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA IMMUNE DISEASES HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANDIFACTURING COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANDIFACTURING COMPANIES 104 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 105 106 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 108 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 109 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBIODY MICROARRAY INDUSTRY 100 ANTIBIODY MICROARRAY INDUSTRY 110 TABLE 42 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	Pan-Cancer	67
TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS Thyroid Cancer TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS TS INFECTIOUS DISEASES DIABETES NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA IMMUNE DISEASES HALA TYPING BAUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET BABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS BABLE 32 PROTEOMIC INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 BABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 BABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS DABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 35 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY PROTEOMICS BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY PROTEOMICS BASED DRUG DISCOVERY MAD DEVELOPMENT INDUSTRY 106 PROTEOMICS BASED DRUG DISCOVERY INDUSTRY 107 TABLE 36 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS BOCHIP INDUSTRY 109 PROTEOMICS BOCHIP INDUSTRY 100 PROTEOMICS BOCHIP INDUSTRY 101 TABLE 36 PROTEOMIC BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 100 CHINA'S BIOCHIP INDUSTRY 110 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS	68
Thyroid Cancer TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS TO INSECTIOUS DISEASES TO DIABETES NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE TO TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA IMMUNE DISEASES HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 BY MASS SPECTROMETRY INDUSTRY TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES CHROMATOGRAPHY PROTEOMICS NORTHLY TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES CHROMATOGRAPHY INDUSTRY 103 CHROMATOGRAPHY PROTEOMICS LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 106 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 39 PROTEOMIC BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PEPTIDE MICROARRAY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 109 TABLE 43 CHINA'S BIOCHIP INDUSTRY 110 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	Prostate Cancer	71
TABLE 28 STATÚS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS INFECTIOUS DISEASES 77 DIABETES 77 DIABETES 77 NEUROLOGICAL DISORDERS 77 ALZHEIMER'S DISEASE 77 ALZHEIMER'S DISEASE 77 TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES 78 SCHIZOPHRENIA 79 IMMUNE DISEASES 81 HLA TYPING 81 AUTOIMMUNE DISEASE 91 HLA TYPING 81 AUTOIMMUNE DISEASE 181 AUTOIMMUNE DISEASE 182 CARDIOVASCULAR DISEASE PREECLAMPSIA 78 TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET 78 CARDIOVASCULAR DISEASE PREECLAMPSIA 78 TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 78 S3 CHAPTER 8 PROTEOMICS INDUSTRY 180 INDUSTRY ACQUISITIONS 78 TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 86 INDUSTRY STRATEGIC ALLIANCES 78 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 78 TABLE 34 MASS SPECTROMETRY INDUSTRY PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 104 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS BIOCHIP INDUSTRIES 109 PROTEOMICS BIOCHIP INDUSTRIES 109 PROTEOMICS BIOCHIP INDUSTRY 100 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 101 TABLE 41 HIGH DENSITY PROTEIN ARRAY INDUSTRY 106 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 107 TABLE 43 CHINA'S BIOCHIP INDUSTRY 108 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 110 TABLE 42 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS	72
INFECTIOUS DISEASES DIABETES DIABETES T77 NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA T99 IMMUNE DISEASES HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 33 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 S6 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES TABLE 35 SECOND-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 36 SISST-TIER MASS SPECTROMETRY COMPANIES 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 109 PROTEOMICS BIOCHIP INDUSTRIES 100 TABLE 31 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRIES 107 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 109 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	Thyroid Cancer	75
DIABETES NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE 777 ALZHEIMER'S DISEASE 778 SCHIZOPHRENIA 79 IMMUNE DISEASES 31 HLA TYPING AUTOIMMUNE DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES 81 HLA TYPING AUTOIMMUNE DISEASE 81 TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULIAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 86 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY TABLE 35 HASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY NDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 108 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 101 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 104 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 42 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS	75
NEUROLOGICAL DISORDERS ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA IMMUNE DISEASES HILA TYPING AUTOIMMUNE DISEASE HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 86 INDUSTRY STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 87 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 101 TABLE 35 FIRST-THER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 104 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 109 ANTIBODY MICROARRAY INDUSTRY 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 101 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	INFECTIOUS DISEASES	77
ALZHEIMER'S DISEASE TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA 79 IMMUNE DISEASES HLA TYPING AUTOIMMUNE DISEASE HLA TYPING AUTOIMMUNE DISEASE HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA 32 PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 111 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 112 FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 114 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRIES PROTEOMICS BIOCHIP INDUSTRIES 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 108 PROTEOMICS BIOCHIP INDUSTRIES PROTEOMICS BIOCHIP INDUSTRIES 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 TABLE 42 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	DIABETES	77
TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES SCHIZOPHRENIA 99 IMMUNE DISEASES 81 HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA 33 TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 86 INDUSTRY ACQUISITIONS 86 INDUSTRY STRATEGIC ALLIANCES TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 104 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 109 PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY (OMPANIES 109 HIGH DENSITY PROTEIN ARRAY (DMPANIES 109 ANTIBODY MICROARRAY (DMPANIES 101 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 101 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 44 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	NEUROLOGICAL DISORDERS	77
SCHIZOPHRENIA 79 IMMUNE DISEASES 81 HLA TYPING 81 AUTOIMMUNE DISEASE 81 AUTOIMMUNE DISEASE 81 AUTOIMMUNE DISEASE 81 TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET 82 CARDIOVASCULAR DISEASE 83 PREECLAMPSIA 83 TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY 86 INDUSTRY ACQUISITIONS 86 INDUSTRY ACQUISITIONS 86 INDUSTRY STRATEGIC ALLIANCES 89 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY 99 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 103 FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 PROTEOMICS BIOCHIP INDUSTRIES 90 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 108 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 44 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	ALZHEIMER'S DISEASE	77
IMMUNE DISEASES HLA TYPING AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 100 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES	78
HLA TYPING AUTOIMMUNE DISEASE AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 85 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 86 INDUSTRY ACQUISITIONS 86 INDUSTRY STRATEGIC ALLIANCES 10 INDUSTRY STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 17 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 103 FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 PROTEOMICS BIOCHIP INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS BIOCHIP INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	SCHIZOPHRENIA	79
AUTOIMMUNE DISEASE TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 86 TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMICS BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRY 107 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 108 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY COMPANIES 110 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	IMMUNE DISEASES	81
TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET CARDIOVASCULAR DISEASE PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES 89 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY; PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 106 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS-BASED DRUG DISCOVERY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	HLA TYPING	81
CARDIOVASCULAR DISEASE PREECLAMPSIA 7ABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 7ABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY 7ABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 107 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 108 PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	AUTOIMMUNE DISEASE	81
PREECLAMPSIA TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 86 TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 87 INDUSTRY STRATEGIC ALLIANCES 89 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 104 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET	82
TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS 83 CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 7ABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES 89 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 7ABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 105 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRIES PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	CARDIOVASCULAR DISEASE	83
CHAPTER 8 PROTEOMICS INDUSTRY INDUSTRY ACQUISITIONS 7ABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES 89 TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 7ABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 107 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 108 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111	PREECLAMPSIA	83
INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 B6 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS	83
INDUSTRY ACQUISITIONS TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 B6 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY 99 TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY		
TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014 INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	CHAPTER 8 PROTEOMICS INDUSTRY	86
INDUSTRY STRATEGIC ALLIANCES TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 89 MASS SPECTROMETRY INDUSTRY 7ABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 111 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 112 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 114 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 108 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	INDUSTRY ACQUISITIONS	86
TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014 MASS SPECTROMETRY INDUSTRY 7ABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 40 KEY PEPTIDE MICROARRAY INDUSTRY 108 HIGH DENSITY PROTEIN ARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014	86
MASS SPECTROMETRY INDUSTRY TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 104 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY INDUSTRY 109 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	INDUSTRY STRATEGIC ALLIANCES	89
TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS 100 TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES 101 TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES 103 CHROMATOGRAPHY INDUSTRY 104 FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW 105 TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES 105 TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES 105 PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 PROTEOMICS BIOCHIP INDUSTRIES 108 PEPTIDE MICROARRAY INDUSTRY 108 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES 109 ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	·	89
TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY 107 TABLE 39 PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 110 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	MASS SPECTROMETRY INDUSTRY	99
TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY 108 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY		100
CHROMATOGRAPHY INDUSTRY FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 110 TABLE 43 CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY	TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES	101
FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113	TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES	103
TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY 106 TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY 108 TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY 109 TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY 110 TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY 111 TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113		103
MANUFACTURING COMPANIES104TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES105PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY106TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY106PROTEOMICS BIOCHIP INDUSTRIES108PEPTIDE MICROARRAY INDUSTRY108TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES108HIGH DENSITY PROTEIN ARRAY INDUSTRY109TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES109ANTIBODY MICROARRAY INDUSTRY110TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES110CHINA'S BIOCHIP INDUSTRY111TABLE 43 CHINA'S BIOCHIP INDUSTRY111TABLE 43 CHINA'S BIOCHIP INDUSTRY112LOAC PROTEOMICS INDUSTRY113		104
PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY 112 LOAC PROTEOMICS INDUSTRY 113		104
TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY		105
PROTEOMICS BIOCHIP INDUSTRIES PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	PROTEOMICS-BASED DRUG DISCOVERY AND DEVELOPMENT INDUSTRY	106
PEPTIDE MICROARRAY INDUSTRY TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY	106
TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	PROTEOMICS BIOCHIP INDUSTRIES	108
HIGH DENSITY PROTEIN ARRAY INDUSTRY TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	PEPTIDE MICROARRAY INDUSTRY	108
TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES	108
ANTIBODY MICROARRAY INDUSTRY TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	HIGH DENSITY PROTEIN ARRAY INDUSTRY	109
TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES	109
CHINA'S BIOCHIP INDUSTRY TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 113	ANTIBODY MICROARRAY INDUSTRY	110
TABLE 43 CHINA'S BIOCHIP INDUSTRY LOAC PROTEOMICS INDUSTRY 112	TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES	110
LOAC PROTEOMICS INDUSTRY 113	CHINA'S BIOCHIP INDUSTRY	111
	TABLE 43 CHINA'S BIOCHIP INDUSTRY	112
TABLE 44 LOAC COMPETITOR LANDSCAPE 114	LOAC PROTEOMICS INDUSTRY	113
	TABLE 44 LOAC COMPETITOR LANDSCAPE	114

TOPIC	PAGE NO.
CHEMICAL PROTEOMICS INDUSTRY	116
ANTIBODY REAGENT INDUSTRY	116
TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)	117
MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY	118
TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES	118
DRIED BLOOD SPOTTING PROTEOMICS INDUSTRY	120
TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY	121
SINGLE CELL PROTEOMICS INDUSTRY	122
TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY	122
CHAPTER 9 PROTEOMICS MARKETS	125
DRIVING FORCES OF PROTEOMICS INDUSTRY GROWTH	125
TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	125
GLOBAL PROTEOMICS MARKETS	126
MARKET SUMMARY	126
TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 (\$ MILLIONS)	127
RESEARCH MARKET	129
TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	129
TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
DRUG DISCOVERY AND DEVELOPMENT MARKETS	130
TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	131
PROTEOMICS DIAGNOSTIC MARKET	132
TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	132
TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	133
TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)	135
TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS	136
TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY	137
TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	139
MASS SPECTROMETRY-BASED PROTEOMIC MARKET	142
TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 (\$ MILLIONS)	142
TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	143
MS-Based Clinical Diagnostics Markets	144
MS Clinical Platforms	145
TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS	145
TABLE 64 MS CLINICAL INDUSTRY	146
TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS	148

TOPIC	PAGE NO.
TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 (\$ MILLIONS)	149
TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	150
BIOCHIP-BASED PROTEOMICS MARKET	151
TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	151
TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	152
TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	153
TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	154
TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	156
PROTEOMICS GEOGRAPHIC MARKET	158
TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	158
TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	159
CHAPTER 10 PROTEOMICS PATENTS	162
BIOCHIP PATENTS	162
PROTEIN ARRAY PATENTS	162
TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	162
LAB-ON-A-CHIP PATENTS	163
TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	163
MASS SPECTROMETRY PATENTS	163
TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)	164
CHAPTER 11 COMPANY PROFILES	166
ABCODIA LTD.	166
ABLYNX NV	166
ACTIVIOMICS LTD.	167
ACTIVX BIOSCIENCES INC.	167
ADVANCED PROTEOME THERAPEUTICS INC.	168
AGILENT TECHNOLOGIES INC.	168
APPLIED MICROARRAYS	169
APPLIED PROTEOMICS	170
ARRAYIT CORP.	171
ASTUTE MEDICAL INC.	172
AVACTA GROUP PLC	173
AYOXXA BIOSYSTEMS GMBH	174
BIOCARTIS NV	174
BIODESIX INC.	175
BIOGNOSYS AG	176
BIOMERIEUX SA	177
BIOPROXIMITY LLC	177
BIO-RAD LABORATORIES INC.	178

TOPIC	PAGE NO.
BIO-TECHNE INC.	178
BRUKER CORP.	179
CAMBRIDGE PROTEIN ARRAYS LTD.	180
CAPRION PROTEOME INC.	181
CAPROTEC BIOANALYTICS GMBH	181
CARMENTA BIOSCIENCE INC.	182
CDI LABORATORIES INC.	182
CRELUX GMBH	182
CRESCENDO BIOSCIENCE	183
CRYSTALGENOMICS INC.	184
CYVEK INC.	184
DANAHER CORP.	185
DIASSESS	186
DIGILAB INC.	187
EPICYPHER INC.	187
EVOTEC AG	187
FLUIDIGM CORP	189
GENERAL ELECTRIC CO.	189
GLAXOSMITHKLINE PLC	189
GLOBAL DISCOVERY BIOSCIENCES	190
GL SCIENCES INC.	191
HEALTHTELL INC.	191
HYBRIGENICS SA	191
TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS	192
IMMUNOVIA AB	193
IMTAKT CORP.	193
INTEGRATED DIAGNOSTICS	193
INDI MOLECULAR	194
IRIS INTERNATIONAL INC.	195
LABCYTE INC.	195
LEAP TECHNOLOGIES INC.	196
LUMINEX CORP.	196
MERCK & CO. INC.	197
MERCK KGAA	197
MICROLYTIC	198
MRM PROTEOMICS INC.	198
MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG	199
MYCARTIS	199
MYRIAD GENETICS INC.	200
NEWOMICS INC.	201
NIRMIDAS BIOTECH INC.	202
OLINK BIOSCIENCE	202
ONCOPLEX DIAGNOSTICS	203
OPKO HEALTH INC.	203
PERKINELMER INC.	204
PERSONALIZED CANCER THERAPY INC.	205
PFIZER INC.	205

TOPIC	PAGE NO.
PHENOMENEX INC.	206
PHYLOGICA LTD.	206
PRESSURE BIOSCIENCES INC.	207
PROMETIC LIFE SCIENCES INC.	208
PROTAGEN AG	209
PROTEA BIOSCIENCES INC.	209
PROTEOCYTE DIAGNOSTICS INC.	211
PROTEOGENIX	211
PROTEOME SCIENCES PLC	211
PROTEOMICS INTERNATIONAL PTY LTD	212
PROTEOVISTA LLC	213
PROVISTA DIAGNOSTICS INC.	213
QIAGEN NV	214
QUANSYS BIOSCIENCES	215
QUANTERIX INC.	215
QUEST DIAGNOSTICS INC.	216
REPLIGEN CORP.	217
RETROGENIX LTD.	217
SAMDI TECH INC.	218
SERA PROGNOSTICS	218
SHIMADZU CORP.	219
SHISEIDO COMPANY LTD.	219
SHOWA DENKO KK	220
SIGMA ALDRICH	220
SINGULEX INC.	221
SISCAPA ASSAY TECHNOLOGIES INC.	221
SOMALOGIC INC.	222
TABLE 79 SOMALOGIC PROTEOMIC METHODS	223
SPHERE FLUIDICS LTD.	223
SPOTON CLINICAL DIAGNOSTICS LIMITED	224
SQI DIAGNOSTICS	224
SYNAGEVA BIOPHARMA	225
T2 BIOSYSTEMS	225
TALKING20 INC.	226
TABLE 80 PERSONALIZED PROTEOMICS COMPANIES	226
THERANOSTICS HEALTH	227
THERMO FISHER SCIENTIFIC INC.	227
THORNE DIAGNOSTICS INC.	229
TOSOH CORP.	229
UNIVERSAL BIOSENSORS LTD.	229
TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE	230
VERMILLION INC.	231
VG LIFE SCIENCES INC.	232
WATERS CORP.	232
XENCOR INC.	233
YMC CO. LTD.	234
ZEPHYRUS BIOSCIENCES INC.	234

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	7
TABLE 1 ARRAY VERSUS LOAC BIOCHIPS	12
TABLE 2 SCOPE OF REPORT	13
TABLE 3 GLOBAL PROTEOMIC MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	14
TABLE 4 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	15
TABLE 5 BIOCHIP INDUSTRY COMPARISONS	16
TABLE 6 MASS SPECTROMETER PLATFORMS	23
TABLE 7 BIOCHIP-BASED PROTEOMIC TECHNOLOGIES	23
TABLE 8 PLANAR-BASED VERSUS BEAD-BASED ARRAYS	24
TABLE 9 ADVANTAGES OF MULTIPLEXING FOR DIAGNOSTICS	25
TABLE 10 TECHNICAL ADVANCES IN PROTEOMICS	28
TABLE 11 PROTEOMIC APPLICATIONS IN DRUG DISCOVERY AND DEVELOPMENT	31
TABLE 12 LARGE-SCALE PROTEOMIC INITIATIVES	36
TABLE 13 STRATEGIES FOR OVERCOMING HIGH-ABUNDANCE PROTEINS IN CLINICAL SAMPLES	41
TABLE 14 ESTIMATED U.S. INCIDENCE AND DEATHS FOR SELECTED CANCERS, 2010 AND 2013	42
TABLE 15 STATUS OF BLADDER CANCER NEXT GENERATION DIAGNOSTICS TESTS	43
TABLE 16 ESTIMATED NUMBER OF ANNUAL BREAST CANCER TREATMENT DECISIONS IN THE U.S. BY CANCER CLASSIFICATION	46
TABLE 17 BREAST CANCER MDX TECHNOLOGY PLATFORMS	47
TABLE 18 STATUS OF NEXT GENERATION BREAST CANCER TESTS	48
TABLE 19 STATUS OF GASTRIC/STOMACH CANCER NEXT GENERATION DIAGNOSTICS TESTS	57
TABLE 20 STATUS OF KIDNEY CANCER NEXT GENERATION DIAGNOSTICS TESTS	58
TABLE 21 FIVE-YEAR SURVIVAL RATES FOR NON-SMALL CELL LUNG CANCER (%)	59
TABLE 22 STATUS OF LUNG CANCER NEXT GENERATION DIAGNOSTICS TESTS	60
TABLE 23 STATUS OF LYMPHOMA CANCER NEXT GENERATION DIAGNOSTICS TESTS	63
TABLE 24 EARLY SCREENING OVARIAN CANCER TESTS	64
TABLE 25 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS	66
TABLE 26 STATUS OF PAN-CANCER NEXT GENERATION DIAGNOSTICS TESTS	68
TABLE 27 STATUS OF PROSTATE CANCER NEXT GENERATION DIAGNOSTICS TESTS	72
TABLE 28 STATUS OF THYROID CANCER NEXT GENERATION DIAGNOSTICS TESTS	75
TABLE 29 ALZHEIMER'S DISEASE DIAGNOSTIC APPROACHES	78
TABLE 30 MULTIPLEX AUTOIMMUNE TESTING MARKET	82
TABLE 31 PREECLAMPSIA DIAGNOSTICS TESTS	83
TABLE 32 PROTEOMIC INDUSTRY ACQUISITIONS, 2012-2014	86
TABLE 33 STRATEGIC ALLIANCES IN THE PROTEOMIC INDUSTRY, 2012-2014	89
TABLE 34 MASS SPECTROMETRY INDUSTRY: PORTER FIVE FORCES ANALYSIS	100
TABLE 35 FIRST-TIER MASS SPECTROMETRY COMPANIES	101
TABLE 36 SECOND-TIER MASS SPECTROMETRY COMPANIES	103
TABLE 37 GLOBAL HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN MANUFACTURING COMPANIES	104
TABLE 38 JAPANESE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY COLUMN LEADING MANUFACTURING COMPANIES	105
TABLE 39 PROTEOMIC-BASED DRUG DISCOVERY INDUSTRY	106
TABLE 40 KEY PEPTIDE MICROARRAY COMPANIES	108

TABLE HEADING	PAGE NO.
TABLE 41 HIGH DENSITY PROTEIN ARRAY COMPANIES	109
TABLE 42 KEY ANTIBODY MICROARRAY COMPANIES	110
TABLE 43 CHINA'S BIOCHIP INDUSTRY	112
TABLE 44 LOAC COMPETITOR LANDSCAPE	114
TABLE 45 ANTIBODY REAGENT MARKET, 2014 (%)	117
TABLE 46 MULTIPLEX PROTEIN IN-VITRO DIAGNOSTICS COMPANIES	118
TABLE 47 DRIED BLOOD SPOT PROTEOMICS INDUSTRY	121
TABLE 48 SINGLE CELL PROTEOMICS INDUSTRY	122
TABLE 49 PROTEOMIC INDUSTRY GROWTH DRIVING FORCES	125
TABLE 50 GLOBAL PROTEOMIC MARKET BY END-USE INDUSTRY, THROUGH 2019 (\$ MILLIONS)	127
TABLE 51 GLOBAL PROTEOMIC RESEARCH MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	129
TABLE 52 GLOBAL PROTEOMIC RESEARCH MARKET BY BIOCHIP PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
TABLE 53 GLOBAL PROTEOMIC DRUG DISCOVERY AND DEVELOPMENT PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	130
TABLE 54 GLOBAL PROTEOMIC BIOCHIP DRUG DISCOVERY AND DEVELOPMENT MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	131
TABLE 55 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY PLATFORM, THROUGH 2019 (\$ MILLIONS)	132
TABLE 56 GLOBAL BIOCHIP DIAGNOSTIC MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	133
TABLE 57 GLOBAL PROTEOMIC DIAGNOSTIC PRODUCT MARKET BY DISEASE TYPE, THROUGH 2019 (\$ MILLIONS)	135
TABLE 58 STATUS OF PROTEOMIC-BASED DIAGNOSTICS FOR DIABETES, NEUROLOGICAL, AUTOIMMUNE, INFECTIOUS DISEASE, HLA TYPING, AND CARDIOVASCULAR DISEASE APPLICATIONS	136
TABLE 59 SEPSIS DIAGNOSTICS INDUSTRY	137
TABLE 60 GLOBAL PROTEOMIC CANCER DIAGNOSTIC PRODUCT MARKET BY INDICATION, THROUGH 2019 (\$ MILLIONS)	139
TABLE 61 GLOBAL MASS SPECTROMETRY MARKET BY PRODUCT TYPE, THROUGH 2019 (\$ MILLIONS)	142
TABLE 62 GLOBAL MASS SPECTROMETRY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	143
TABLE 63 MRM-MS VERSUS MALDI MS IN CLINICAL APPLICATIONS	145
TABLE 64 MS CLINICAL INDUSTRY	146
TABLE 65 PHOSPHOPROTEOMICS PLATFORMS FOR CANCER APPLICATIONS	148
TABLE 66 GLOBAL MASS SPECTROMETRY INSTRUMENT PROTEOMICS MARKET BY TECHNIQUE, THROUGH 2019 (\$ MILLIONS)	149
TABLE 67 GLOBAL MASS SPECTROMETRY CONSUMABLE MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	150
TABLE 68 GLOBAL PROTEOMIC BIOCHIP MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	151
TABLE 69 GLOBAL PROTEOMIC ARRAY MARKET BY TYPE, THROUGH 2019 (\$ MILLIONS)	152
TABLE 70 GLOBAL PROTEOMIC BIOCHIP MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	153
TABLE 71 GLOBAL PROTEOMIC ARRAY MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	154

TABLE HEADING	PAGE NO.
TABLE 72 GLOBAL PROTEOMIC LOAC MARKET BY END-USER INDUSTRY, THROUGH 2019 (\$ MILLIONS)	156
TABLE 73 GLOBAL PROTEOMIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	158
TABLE 74 GLOBAL PROTEOMIC DIAGNOSTIC MARKET BY REGION, THROUGH 2019 (\$ MILLIONS)	159
TABLE 75 ARRAY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	162
TABLE 76 LAB-ON-A-CHIP-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014	163
TABLE 77 MASS SPECTROMETRY-RELATED PROTEOMIC PATENTS BY REGION, 2004-2014 (NO. OF PATENTS)	164
TABLE 78 APPLICATIONS FOR Y2H AND YCHEMH PROTEOMICS PLATFORMS	192
TABLE 79 SOMALOGIC PROTEOMIC METHODS	223
TABLE 80 PERSONALIZED PROTEOMICS COMPANIES	226
TABLE 81 UNIVERSAL BIOSENSORS DIAGNOSTIC PIPELINE	230

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL PROTEOMIC MARKET BY END-USER INDUSTRY, 2013-2019 (\$ MILLIONS)	7
FIGURE 1 MASS SPECTROMETRY GENERALIZED WORKFLOW SCHEMATIC	18
FIGURE 2 PROTEOMIC BIOCHIP AND ARRAY FORMATS	19
FIGURE 3 CHROMATOGRAPHY PROTEOMICS WORKFLOW	104